Download this report now to access this exclusive content
This report highlights the limitations of monoclonal antibodies in targeting tumour antigens and discusses how genetically engineered medicinal products are leveraging T-cell receptors to broaden immune targets for cancer treatment. Additionally, a new study suggests gene therapy may combat ARVC across various disease stages.
This report contains the following articles:
- Unlocking the power of stem cell therapy
- Potential new therapies for primary open-angle glaucoma
- Mechanisms underlying pioneer TF-mediated gene repression
- Decoding stem cells for personalised regenerative medicine
- Gamma delta T cells: a rising star in cancer therapy
- New algorithm can predict when cancer will resist chemotherapy
- Combatting osteoarthritis with cartilage replacement therapy
- Combatting HIV using gene therapy
- Quantify and identify AAV aggregates with Aura GT
- Replacing the PKp2 gene prolongs survival in ARVC patients
- T-cell receptors offer window to the cell for a new class of cancer therapeutics.
Moreover, researchers have developed a nanomedicine loaded with siRNAs, showing a significant reduction in HIV replication. Furthermore, the report explores the unique characteristics of γδ T cells for potential therapeutic applications in cancer treatment, as well as proactive strategies for regenerative cell therapy development, including addressing manufacturing challenges and streamlining processes to expedite transformative therapies.
Expert insights from:
- Dr Kristian Tryggvason, CEO & Founder, Alder Therapeutics
- Dr Suresh Nair, Physician in Chief of Lehigh Valley Topper Cancer Institute
- Kate Rochlin, COO – IN8bio, Inc.
- Dr Alexander Scheer, Founder of Scheer Medical Wellness
